Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 38.75 GBp
Change Today -0.25 / -0.64%
Volume 7.2M
As of 11:35 AM 11/30/15 All times are local (Market data is delayed by at least 15 minutes).

sinclair is pharma plc (SPH) Snapshot

38.75 GBp
Previous Close
39.00 GBp
Day High
39.25 GBp
Day Low
38.50 GBp
52 Week High
07/23/15 - 48.00 GBp
52 Week Low
02/17/15 - 31.50 GBp
Market Cap
Average Volume 10 Days
-0.01 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for SINCLAIR IS PHARMA PLC (SPH)

Related News

No related news articles were found.

sinclair is pharma plc (SPH) Related Businessweek News

No Related Businessweek News Found

sinclair is pharma plc (SPH) Details

Sinclair IS Pharma plc, a specialty pharmaceutical company, provides surface technology and delivery systems for aesthetics, wound care, and skin care treatments worldwide. The company’s aesthetic dermatology solutions include Kelo-cote, a topical silicone gel used for the management and prevention of hypertrophic and keloid scars; Kelo-Stretch, which helps in rebuilding damaged collagen and regaining skin elasticity; Sculptra, a volumizer designed to stimulate natural collagen growth; Perfectha for the treatment of wrinkles and facial contours; Ellansé, which offers four dermal filler options for facial aesthetic treatments; and Silhouette Soft, a skin tightening and own collagen stimulator. Its wound care products comprise Flammazine and Flammacerium that are used in the prevention and treatment of severe burns and wounds; and Aloclair Plus for relieving the pain caused by aphthous mouth ulcers and other minor oral lesions. The company’s skin care products include Atopiclair, a non-steroidal topical treatment for the symptomatic relief of atopic, contact allergic, and irritant dermatitis; Papulex, a dermocosmetic product used for cleansing, hydrating, and protecting acne prone skin; Sebclair for the management of skin and scalp seborrhoeic dermatitis; and Bio-Taches products for preventing and reducing pigmentation disorders, such as chloasma, melasma, or dyschromia. Further, it offers other products consisting of Variquel/Haemopressin for the treatment of bleeding oesophageal varices; Aloxi, a 2nd generation 5HT3 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting associated with highly emetogenic chemotherapy and moderately emetogenic chemotherapy; and Decapinol for plaque management. Sinclair IS Pharma plc offers its solutions to hospitals, plastic surgeons, dermatologists, and pharmacists. The company was founded in 1971 and is headquartered in London, the United Kingdom.

Founded in 1971

sinclair is pharma plc (SPH) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 630.0K GBP
Chief Operating Officer and Director
Total Annual Compensation: 392.0K GBP
Compensation as of Fiscal Year 2014.

sinclair is pharma plc (SPH) Key Developments

Sinclair IS Pharma plc Reports Unaudited Consolidated Earnings Results for the Year Ended June 30, 2015; Provides Sales Guidance for the Fiscal Full Year of 2016 and 2017

Sinclair IS Pharma plc reported unaudited consolidated earnings results for the year ended June 30, 2015. For the period, the company reported operating profit of GBP 4,543,000 against loss of GBP 1,785,000 for the same period in the last year. Loss before taxation was GBP 8,152,000 against GBP 4,441,000 for the same period in the last year. Loss for the year from continuing operations was GBP 7,208,000 against GBP 4,093,000 for the same period in the last year. Loss attributable to the owners of the parent was GBP 7,208,000 against GBP 5,301,000 for the same period in the last year. Loss per basic and diluted from continuing operation share was 1.5 pence against 0.9 pence for the same period in the last year. Loss per basic and diluted share for the year was 1.5 pence against 1.2 pence for the same period in the last year. Adjusted EBITDA was GBP 17,057,000 against GBP 10,032,000 for the same period in the last year. Net cash generated from operating activities was GBP 4,252,000 against net cash used in operating activities of GBP 6,772,000 for the same period in the last year. Adjusted basic EPS increased by 54% to 2.0 pence from 1.3 pence in 2014. Net debt was GBP 42.2 million against GBP 40.2 million a year ago. Reported revenue was held back by foreign exchange headwinds due to the strength of sterling versus the euro, in particular, which reduced headline revenue by GBP 3.1 million on a constant currency basis. Revenue was also reduced by GBP 2.3 million versus fiscal year 2014 from products disposed in the year or during last year. Adjusted basic EPS increased by 54% as a result of the improvement in EBITDA but partly offset by increased interest costs. Revenue was GBP 75.9 million against GBP 63.6 million a year ago. Purchases of property, plant and equipment was GBP 826,000 against GBP 355,000 a year ago. Purchase of intangible assets was GBP 1,401,000 against GBP 1,368,000 a year ago. The company provided sales guidance for the fiscal full year 2016 and 2017. Sales growth for fiscal 2016 is expected to be in the range of 8% to 25% as these changes work through the system. In contrast in market sales growth expected to be approximately 40% compared to fiscal 2015. On a reported basis, very strong sales growth is expected to return in first half of fiscal 2017.

Alliance Pharma plc, Sinclair IS Pharma plc - M&A Call

To discuss the strategic disposal of its non-aesthetics business to Alliance Pharma plc

Alliance Pharma plc, Sinclair IS Pharma plc - M&A Call

To discuss the conditional agreement with Sinclair IS Pharma plc to acquire certain assets and businesses principally focused on dermatology for a consideration of £127.5 million, plus an estimated £4.7 million for inventory


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPH:LN 38.75 GBp -0.25

SPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPH.
View Industry Companies

Industry Analysis


Industry Average

Valuation SPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SINCLAIR IS PHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at